Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer.
作者信息
Qin Angel, Kalemkerian Gregory P
机构信息
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
出版信息
Transl Cancer Res. 2016 Nov;5(Suppl 6):S1142-S1144. doi: 10.21037/tcr.2016.11.22.
Abstract
摘要
相似文献
1
Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer.顺铂、依托泊苷和伊立替康用于复发性小细胞肺癌
Transl Cancer Res. 2016 Nov;5(Suppl 6):S1142-S1144. doi: 10.21037/tcr.2016.11.22.
2
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.联合顺铂、依托泊苷和伊立替康化疗与拓扑替康单药二线治疗敏感复发性小细胞肺癌患者（JCOG0605）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.
3
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.伊立替康联合顺铂与依托泊苷联合顺铂治疗广泛期小细胞肺癌的比较。
N Engl J Med. 2002 Jan 10;346(2):85-91. doi: 10.1056/NEJMoa003034.
4
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.一种用于小细胞肺癌的新型伊立替康方案的剂量密集疗法。
Oncology (Williston Park). 2003 Jul;17(7 Suppl 7):17-21.
5
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.安鲁米星与每周顺铂/依托泊苷/伊立替康治疗复发性小细胞肺癌患者的比较
Clin Lung Cancer. 2017 Mar;18(2):234-240.e2. doi: 10.1016/j.cllc.2016.09.005. Epub 2016 Oct 25.
6
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.依托泊苷和顺铂与伊立替康和顺铂在接受依托泊苷和顺铂联合同期加速超分割胸部放射治疗的局限期小细胞肺癌患者中的比较（JCOG0202）：一项随机 3 期研究。
Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3.
7
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.基于 JCOG0605 试验的敏感复发小细胞肺癌的成本效果分析。
Clin Transl Oncol. 2018 Jun;20(6):768-774. doi: 10.1007/s12094-017-1787-y. Epub 2017 Nov 2.
8
Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.伊立替康联合顺铂治疗广泛期小细胞肺癌患者：2000 - 2006年美国医学肿瘤学家的使用模式
J Thorac Oncol. 2007 Oct;2(10):953-6. doi: 10.1097/JTO.0b013e318153f8db.
9
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).顺铂、伊立替康和依托泊苷联合用药每周或每4周给药一次用于广泛期小细胞肺癌的随机II期研究（JCOG9902-DI）
Ann Oncol. 2003 May;14(5):709-14. doi: 10.1093/annonc/mdg213.
10
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.一项比较顺铂联合伊立替康或依托泊苷治疗广泛期未经治疗的小细胞肺癌患者的多中心国际随机 III 期研究。
Ann Oncol. 2010 Sep;21(9):1810-1816. doi: 10.1093/annonc/mdq036. Epub 2010 Mar 15.
引用本文的文献
1
Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model.在C-7位带有咔唑的诺氟沙星衍生物FQB-1在实验性肺癌模型中诱导细胞毒性、抗增殖和抗肿瘤作用。
Pharmaceuticals (Basel). 2025 Apr 30;18(5):664. doi: 10.3390/ph18050664.
2
Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!ARF 肿瘤抑制蛋白在肺癌中的作用：是时候一锤定音了！
Mol Cell Biochem. 2021 Mar;476(3):1365-1375. doi: 10.1007/s11010-020-03996-0. Epub 2021 Jan 3.
3
Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP).从不吸烟者与重度吸烟者中小细胞肺癌的多基因突变分析及临床特征（Geno1.3-CLICaP）
Front Oncol. 2019 Apr 17;9:254. doi: 10.3389/fonc.2019.00254. eCollection 2019.
本文引用的文献
1
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.联合顺铂、依托泊苷和伊立替康化疗与拓扑替康单药二线治疗敏感复发性小细胞肺癌患者（JCOG0605）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.
2
Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.对于接受二线化疗的复发性小细胞肺癌患者，体能状态和对一线化疗的敏感性是重要的预后因素。
Cancer. 2008 Nov 1;113(9):2518-23. doi: 10.1002/cncr.23871.
3
Prophylactic cranial irradiation in extensive small-cell lung cancer.广泛期小细胞肺癌的预防性全脑照射
N Engl J Med. 2007 Aug 16;357(7):664-72. doi: 10.1056/NEJMoa071780.
4
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.一项III期试验，比较单纯支持性治疗与支持性治疗联合口服拓扑替康用于复发小细胞肺癌患者的疗效。
J Clin Oncol. 2006 Dec 1;24(34):5441-7. doi: 10.1200/JCO.2006.06.5821.
5
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer.毒性调整后的拓扑替康疗法在复发性小细胞肺癌中的疗效。
Eur Respir J. 2006 Jun;27(6):1183-9. doi: 10.1183/09031936.06.00015605. Epub 2006 Feb 15.
6
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).复发性小细胞肺癌的二线化疗。顺铂和依托泊苷（EP方案）或环磷酰胺、表柔比星和长春新碱（CEV方案）一线治疗后交叉方案的结果。
Lung Cancer. 2005 May;48(2):251-61. doi: 10.1016/j.lungcan.2004.10.016. Epub 2004 Dec 15.
7
A phase II study of topotecan in patients with relapsed small-cell lung cancer.拓扑替康用于复发性小细胞肺癌患者的II期研究。
Clin Lung Cancer. 2003 Jan;4(4):224-8. doi: 10.3816/clc.2003.n.002.
8
Reinduction chemotherapy in small cell lung cancer.
Eur J Cancer Clin Oncol. 1987 Nov;23(11):1697-9. doi: 10.1016/0277-5379(87)90452-4.
Zotero 插件